
Bristol Myers Squibb (BMS) is to purchase MyoKardia for $13 billion to boost its heart disease treatments portfolio. The deal …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

